ORLANDO, Fla. John Spertus, MD, MPH, principal investigator of the late-breaking clinical trial, PRISM, reviewed a new way to approach the consent form process that allows for greater dialogue between patients and physicians for combined decision-making with Cardiovascular Business.

ORLANDOC. Michael Gibson, MD, principal investigator of the ATLAS-ACS trial, sat down with Cardiovascular Business to discuss the rationale and objectives that informed the design of the trial, as well as the much-anticipated results. The late-breaking clinical trial was presented Nov. 13 at the American Heart Association scientific sessions.

SAN FRANCISCOAs newer, more expansive procedures such as transcathter aortic valve implementation (TAVI) emerge, it will be imperative for cath labs to integrate and establish multidisciplinary teams rather than face off in turf battles, Sam Radhakrishnan, MD, said during a Nov. 10 presentation at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

SAN FRANCISCOAt two years, in patients with symptomatic severe aortic stenosis who are not suitable candidates for surgery, transcatheter aortic valve implantation remained superior to standard therapy with incremental benefit from one to one years, reducing the rates of all-cause mortality, cardiovascular mortality and repeat hospitalization, based on the PARTNER B data presented Nov. 10, as a late-breaking clinical trial at TCT.11. However, there were more neurologic events in TAVI patients versus standard therapy with five new events between one and two years in TAVI patients.

SAN FRANCISCODespite early termination of the STACCATO trial and criticism from his colleagues, Leif Thuesen, MD, of the department of cardiology at Aarhus University Hospital in Skejby, Denmark, defend the trial, which compared a new aortic vavular treatment with surgery during a Nov. 10 press conference at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

SAN FRANCISCOThe use of the radial approach during PCI can help reduce bleeding complications as well as cardiovascular death in STEMI patients, according to the results of the RIFLE STEACS trial presented Nov. 10 during a late-breaking clinical trial session at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting. Trial presenter Enrico Romagnoli, MD, PhD, even went as far as to say that the radial access site should become the recommended access site for these patients undergoing PCI.

SAN FRANCISCOTime for platelet function to return to baseline reflected the extent of platelet inhibition at 24 hours post-loading dose, and those treated with prasugrel required a longer time for recovery compared with clopidogrel, according to a scientific poster displayed Nov. 8 at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

SAN FRANCISCOWhen used as a bridging strategy to CABG after thienopyridine discontinuation, cangrelor achieves levels of platelet inhibition known to be associated with a low risk of thrombotic events, without increased risk of bleeding before or during CABG, according to the BRIDGE late-breaking clinical trial presented Nov. 9 at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) conference.